Skip to business profile
Loading public business profile Reading the canonical Directory record.
Loading profile
Public Directory
Public business profile

Business profile

Loading canonical business information.

— — —
Registry verification — business evidence
Directory Score — Public record strength, not a rating
Data confidence — public data confidence
Freshness — record lifecycle
ASG Gateway —
Business profile

About

For people, developers and AI

AI-readable discovery

Public information

Read the structured business information and inspect the published discovery documents.

Machine-readable documents do not by themselves establish a live AI agent, checkout or business ownership.

Talk to the business

Request a quote

Loading quote availability…

Public business listing Owner sign-in Suggest a correction
Report this listing

Tell us what needs reviewing. Removal requests are reviewed before any change is made.

Request removal
Profile information

Publication, owner access and business registry verification are separate. Verification badges describe the checks completed; public references identify this listing.

Structured public business summary

Georgetown Law Technology Review

Georgetown Law Technology Review Georgetown Law Technology Review Home Masthead Issues Scholarship Articles Notes Essays Tech Explainers Legal Impressions Submissions Write-On Symposium Search for: Privacy, Power & Empowerment: How Period Trackers Fail to Protect Women Abigail Patchen Period-tracking applications occupy a large share of the FemTech industry, offering users intimate insights into their reproductive health while simultaneously exposing them to unprecedented privacy risks. Period-tracking apps regularly disseminate highly sensitive health data under the protection of the notice and consent paradigm of privacy law, an outdated framework that places the burden of privacy […] Read More AI in Pharmaceutical Research and Development: A Tiered Proposal Realigning Regulatory Exclusivity Periods Ingrid Villarreal This Note examines how artificial intelligence (“AI”) is fundamentally transforming pharmaceutical research and development (“R&D”), altering the cost, risk, and timelines that traditionally justify regulatory exclusivity protections. As AI-enabled technologies accelerate drug discovery and increase clinical success rates, the traditional assumptions supporting lengthy exclusivity periods are becoming less persuasive.

Global

Official website

Machine-readable JSON profile

Business nature

Primary business nature
Not provided
Customer market
Not provided

Operating hours

Hours not provided.

Categories

  • Other Businesses & Services (primary)

Public contacts

Directory status

Registry verification: Not Registry Verified

Directory score: 74

Public source evidence